<DOC>
	<DOCNO>NCT01909869</DOCNO>
	<brief_summary>One purpose study assess preliminary safety feasibility , provide relate information evidence design pivotal randomize control trial.the purpose assess performace stent delivery system .</brief_summary>
	<brief_title>A Pilot First In Man Study EXCEL-Ⅱto Treat Patients With de Novo Coronary Artery Lesions</brief_title>
	<detailed_description>1 . Single-center , prospective , pilot study 2 . De novo , coronary artery , single vessel single lesion 3 . Sample size = 45 4 . Follow- clinical phone 1-month,9-month annually 2 5 year 5 . Randomization 2:1 Angio OCT schedule follow-up hospital 6 . Follow-up Angio OCT randomize 30 patient 4-month 15 patiens 12-month</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Chromium</mesh_term>
	<mesh_term>Cobalt</mesh_term>
	<mesh_term>Chlorhexidine</mesh_term>
	<mesh_term>Chlorhexidine gluconate</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . 18yrs≤Age≤75yrs . 2 . De novo lesion native coronary artery . 3 . Single target vessel single target lesion . 4 . Lesion length ≤32mm . 5 . RVD 2.5mm～4.0mm . 6 . DS % ≥70 % visual estimation . 7 . Target lesion could cover one stent . 8 . Subjects willing follow specify requirement followup . 9 . A process subject voluntarily confirm willingness participate particular trial , inform aspect trial relevant subject 's decision participate . Informed consent document mean write , sign date informed consent form . 1 . AMI within one week . 2 . CTO ( TIMI0 ) , LM lesion , ostial lesion , graft vessel lesion , bifurcation ( side branch RVD≥2.5mm ) , ISR , mutivessel disease need treat . 3 . Severe calcified lesion unable predilate . 4. extremely tortuous proximal lesion inadequate stent delivery . 5 . NYHA≥Ⅲ LVEF≤40 % . 6 . Prior stenting within 1 year . 7 . Pregnancy lactation , plan postoperative pregnancy lactation . 8 . Subjects bleed tendency blood coagulation dysfunction PCI contraindication , anticoagulant therapy taboo ca n't continue DAPT healer least 1 year . 9 . There diseases ( cancer , malignant tumor , congestive heart failure , organ transplantation candidate ) abuse history ( alcohol cocaine heroin , etc . ) , scheme compliance poor , interference relate data explanation limited life ( &lt; 1 year ) . 10 . To aspirin heparin clopidogrel cobalt chromium alloy rapamycin PLA polymer contrast agent one allergy . 11 . Serious liver kidney function complete person . 12 . The investigator think fit enroll study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>MACE</keyword>
	<keyword>TVR</keyword>
	<keyword>MI</keyword>
	<keyword>TLF</keyword>
	<keyword>Death</keyword>
</DOC>